12 min listen
Valproic Acid–Associated Hyperammonemia: A Systematic Review
Valproic Acid–Associated Hyperammonemia: A Systematic Review
ratings:
Length:
13 minutes
Released:
Apr 25, 2023
Format:
Podcast episode
Description
Hyperammonemia is an adverse effect that poses clinical uncertainty regarding the prescription of valproic acid (VPA) use. The prevalence of symptomatic and asymptomatic hyperammonemia and its relationship to VPA concentration is not well established. In this podcast, clinical pharmacists Michelle Gnrya and Yiu-Ching Jennifer Wong of St. Paul’s Hospital in Vancouver discuss their systematic review that summarizes evidence available regarding VPA-associated hyperammonemia and its prevalence, clinical outcomes, and management. Their review is published in the May-June 2023 issue of the Journal of Clinical Psychopharmacology. The review found various risk factors for this common adverse effect, including concomitant medications, liver injury, and defects in carnitine metabolism. With VPA discontinued, most symptomatic patients returned to baseline mental status with normalized ammonia level. Further studies are required to determine the benefit of routine ammonia level monitoring and to guide the management of VPA-associated hyperammonemia.
Released:
Apr 25, 2023
Format:
Podcast episode
Titles in the series (41)
Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?: Psychotic depression is a severely disabling illness and is more common than is generally realized. Unfortunately, there is no FDA-approved medication for its treatment. In this podcast, the Editor-in-Chief of the Journal of Clinical... by The Journal of Clinical Psychopharmacology Podcast